Upadacitinib for alopecia areata: 55% regrowth in two global phase 3 trials

What just happened

The Medical Republic reported today on two large phase 3 trials — UP-AA1 and UP-AA2 — published in JAMA Dermatology this month, evaluating upadacitinib for severe alopecia areata. The results are among the strongest efficacy data for this condition seen in a randomised controlled setting.

Alopecia areata is an autoimmune condition. The immune system attacks hair follicles, causing them to stop producing hair. The extent varies enormously — from small patches that regrow spontaneously, through to complete loss of scalp, eyebrow, eyelash, and body hair that persists for years or decades. The condition affects men and women, but the psychosocial weight lands unevenly. For many women, the loss of hair is not a cosmetic inconvenience — it is a sustained assault on identity, professional life, and social confidence, often in the absence of any visible illness that the outside world can see.

Until recently, the treatment options for severe, persistent alopecia areata were genuinely limited. Topical and intralesional steroids, contact sensitisers, PUVA therapy — none worked reliably at scale, and none showed the kind of efficacy that transformed outcomes for a meaningful proportion of patients. The JAK inhibitor class has changed that calculus.

Both-and

What the trials showed

UP-AA1 enrolled 676 patients and UP-AA2 enrolled 723 patients across global sites. Participants had severe alopecia areata — mean baseline SALT scores of 83–84, meaning close to total scalp hair loss. Roughly 60% of participants were women, and the mean age was around 35. About 8–10% were adolescents.

At 24 weeks, 54–55% of patients on the 30mg dose reached a SALT score of 20 or less, compared with 1.5–3.4% on placebo. The 15mg dose showed 44–45% response. To put the placebo figure in context: without treatment, essentially nobody with severe longstanding alopecia areata achieves meaningful regrowth on their own within 24 weeks.

Complete hair regrowth — SALT 0, measured scalp — occurred in 20–22% on the 30mg dose versus under 1% on placebo. This was a secondary endpoint, and the authors note it was not a ranked key endpoint in previous JAK inhibitor approvals for this condition. Its inclusion here, and its statistical significance, is clinically meaningful.

Response appeared early: at week 12, 29% on the 30mg dose had already reached SALT ≤20. For a patient who has been functionally bald for years, hair at 12 weeks is not a small thing.

Psychosocial outcomes were measured alongside hair regrowth using validated anxiety and depression scales. Both improved significantly in the treatment groups — a reminder that the sizable psychological burden of severe alopecia areata is not a secondary concern. It is part of the disease itself.

The safety picture — and what it means for clinical practice

JAK inhibitors as a class carry a safety profile that requires acknowledgement. In these trials, common adverse events included acne (16% on 30mg vs 4% placebo), upper respiratory infections, and elevated creatine phosphokinase. Neutropenia occurred in about 4% on 30mg versus under 1% on placebo. Serious adverse events occurred in 23 patients across both trials — primarily on the 30mg dose — with no deaths and no serious infections in adolescents.

These are not trivial adverse events, but they need to be held against what the alternative looks like: severe, persistent alopecia areata that has not responded to available treatments, with the significant psychological burden that carries.

The question of access is, as usual, the one that matters most for Australian patients right now. TGA has approved baricitinib and ritlecitinib for severe alopecia areata in adults, and ritlecitinib also in adolescents — but neither is currently PBS-listed for this indication. That means substantial out-of-pocket cost for most patients. Upadacitinib — already TGA-approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and other conditions — has not yet received a TGA indication for alopecia areata. The UP-AA1 and UP-AA2 data are the kind of evidence that supports a regulatory application.

The longer question about autoimmune disease and general practice

Severe alopecia areata tends to fall between the cracks of the Australian health system. It is not life-threatening. It does not have an MBS item specifically designed around it. It often persists for years, sometimes decades, in patients who have cycled through topical options without success and who have not been referred to a dermatologist with a specific interest in autoimmune hair disorders.

The JAK inhibitor data does not change what a GP can prescribe tomorrow — but it changes the referral conversation. A patient who has had severe alopecia areata for three or more years and has not seen a dermatologist with specific expertise deserves that referral, because the evidence base for effective treatment has now substantially shifted.

My two cents

For a condition that the system has historically treated as cosmetic and therefore optional to address, these trial numbers are genuinely significant. Two randomised controlled trials, over 1,300 patients combined, 20–22% complete scalp regrowth on the 30mg dose — in people who had been, on average, mostly bald for more than a decade.

If you have severe alopecia areata and have been told there is not much to offer, it is worth revisiting that conversation with a dermatologist who is across the current evidence. The treatment landscape has changed. The access pathways are still catching up — but the science is no longer the limiting factor.

Verdict: yes — the phase 3 evidence is robust, and severe alopecia areata now has meaningful treatment options worth knowing about.

---

Sources cited

1. Further evidence for JAK inhibitors in severe AA. Medical Republic, 20 August 2026. https://www.medicalrepublic.com.au/further-evidence-for-jak-inhibitors-in-severe-aa/128219